Effective September 11, 2006 Atrium Biotechnologies Inc. (TSE: ATB) has acquired the assets of the London, Ontario-based Douglas Laboratories Canada.
According to Richard Bordeleau, President of Atrium's Health & Nutrition Division:
This acquisition provides Atrium with a platform to develop the Canadian healthcare professional market not only for the Douglas Laboratories brand but also for the Pure Encapsulations brand which is not currently being sold in Canada. This acquisition further reinforces our current leadership position in North America and marks another step in our strategy to control access to markets and build solid organic growth for our brands.
Atrium Biotechnologies Inc., a leading developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutrition industries, will benefit from the expertise and support of DL Canada's current management and staff (who are staying on to ensure the successful integration and to sustain its growth) as well as their excellent knowledge of the Canadian nutritional supplement market.
Find more details from the press release (a pdf file).
Comment Preview